Muscle-Regenerating Peptide Composition for Sarcopenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods to prevent muscle loss and promote muscle mass, such as exercise and protein supplementation, are ineffective for elderly individuals with sarcopenia, and there is a lack of therapeutic agents to address this condition.
Innovation Solution
A peptide with a specific amino acid sequence (SEQ ID NO: 1) is developed, which enhances the expression of myogenin, myogenic factor 5, and myosin heavy chain, while reducing inflammatory proteins, and is formulated into pharmaceutical and food compositions to promote muscle cell differentiation and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exercise and protein supplementation are used to prevent muscle loss, then muscle mass may be maintained in healthy individuals, but these methods are ineffective for elderly individuals with sarcopenia
Solution Approach 1:
The patent changes the fundamental parameter from conventional exercise and dietary interventions to a peptide-based therapeutic agent with specific amino acid sequence (SEQ ID NO: 1). This peptide directly activates muscle regeneration pathways through molecular mechanisms, transforming the approach from indirect support (exercise/protein) to direct cellular stimulation, thereby achieving reliable effectiveness in elderly sarcopenia patients who cannot respond to conventional methods
Solution Approach 2:
The peptide acts as a biological intermediary that mediates between the administration form and the muscle regeneration response. By using a peptide with specific sequences (SEQ ID NO: 1) that can penetrate cell membranes and activate intracellular signaling pathways, the patent creates an effective bridge that conventional exercise and protein intake cannot achieve in elderly sarcopenia patients
2Reliability
If no therapeutic agent is developed for sarcopenia, then current treatment relies on exercise and supplementation, but this leaves muscle loss untreated and progressive
Solution Approach 1:
The patent extracts the essential therapeutic function from complex conventional treatments (exercise programs, dietary supplements) and concentrates it into a single peptide molecule with specific amino acid sequence (SEQ ID NO: 1). This extracted peptide directly targets and activates muscle regeneration pathways, providing reliable therapeutic efficacy while simplifying the treatment approach to a single administered substance rather than multiple complex interventions
3Quantity of substance
If muscle protein synthesis is promoted through anabolic signaling, then muscle mass increases, but without specific peptide intervention, this process remains insufficient for sarcopenia
Solution Approach 1:
The patent changes the molecular parameter by introducing a peptide with a specific amino acid sequence (SEQ ID NO: 1) that directly activates anabolic signaling pathways at the cellular level. This peptide modifies the regulatory parameters of muscle protein synthesis, transforming it from a passive process that relies on general nutrition and exercise to an actively stimulated process that reliably increases protein synthesis rate and restores muscle mass in sarcopenia patients
Data Source
AI summary
The present application relates to a peptide exhibiting muscle loss prevention and muscle mass promotion activities, and use thereof, and provides: a peptide consisting of an amino acid sequence of SEQ ID NO: 1; a pharmaceutical composition for preventing or treating a muscle disease, comprising the peptide as an active ingredient; and a food composition for preventing or ameliorating a muscle disease, comprising the peptide as an active ingredient.